8.03
-0.02 (-0.25%)
| 前收盘价格 | 8.05 |
| 收盘价格 | 8.11 |
| 成交量 | 1,150,409 |
| 平均成交量 (3个月) | 1,948,092 |
| 市值 | 1,391,778,688 |
| 价格/销量 (P/S) | 159.42 |
| 股市价格/股市净资产 (P/B) | 2.23 |
| 52周波幅 | |
| 利润日期 | 6 Nov 2025 |
| 营业利益率 (TTM) | -1,105.21% |
| 稀释每股收益 (EPS TTM) | -2.20 |
| 季度收入增长率 (YOY) | -23.30% |
| 总债务/股东权益 (D/E MRQ) | 6.54% |
| 流动比率 (MRQ) | 19.96 |
| 营业现金流 (OCF TTM) | -271.99 M |
| 杠杆自由现金流 (LFCF TTM) | -155.22 M |
| 资产报酬率 (ROA TTM) | -28.82% |
| 股东权益报酬率 (ROE TTM) | -45.46% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Relay Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | -3.5 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.75 |
|
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.48% |
| 机构持股比例 | 105.68% |
| 52周波幅 | ||
| 中 | 6.00 (-25.28%) | |
| 总计 | 1 保留 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wells Fargo | 07 Nov 2025 | 6.00 (-25.28%) | 保留 | 6.05 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合